Titre : | Ecstasy: pharmacodynamic and pharmacokinetic interactions (2004) |
Titre traduit : | (Ecstasy : interactions pharmacodynamiques et pharmacocinétiques) |
Auteurs : | OESTERHELD J. R. ; S. C. ARMSTRONG ; COZZA K. L. |
Type de document : | Article : Périodique |
Dans : | Psychosomatics (Vol.45, n°1, March-April 2004) |
Article en page(s) : | 84-87 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés MDMA-ECSTASY ; PHARMACOLOGIE ; PHARMACOCINETIQUE ; RAVE ; POLYCONSOMMATION ; TOXICITE |
Résumé : | At "raves," young people dance and ingest illicit drugs, the most common of which is MDMA (N-methyl-3,4,-methylenedioxymethamphetamine) or "ecstasy." This drug is metabolized principally through the cytochrome P450 (CYP450) 2D6 enzyme. Pharmacokinetic drug-drug interactions can occur if MDMA is combined with other recreational or therapeutic drugs that are 2D6 inhibitors. Ecstasy concentration may increase to cause toxicity. Since ecstasy is pro-serotonergic, it may also be involved in pharmacodynamic drug-drug interactions when other pro-serotonergic drugs are combined with it, leading to a central serotonin syndrome. Some drugs are both pro-serotonergic and CYP450 2D6 inhibitors and, if co-administered with ecstasy, may cause both pharmacokinetic and pharmacodynamic drug-drug interactions. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 24 |
Affiliation : | Spurwink School, Portland, Me, USA |
Numéro Toxibase : | 1300913 |
Centre Emetteur : | 13 OFDT |
Cote : | A01694 |
Accueil